India Boosts Pharma-MedTech Innovation with PRIP Workshop
ECONOMY & POLICY

India Boosts Pharma-MedTech Innovation with PRIP Workshop

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilisers, Government of India, held a workshop on the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme on March 12, 2025. Senior officials from key government departments participated, including Shri Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); Shri S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr. N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General of CSIR; and Dr. Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, ICMR.

The workshop focused on strengthening India’s innovation ecosystem in pharmaceuticals and medical technology. Shri Amit Agrawal highlighted the sector's rapid growth, noting the rising global share of advanced technologies like antibody-drug conjugates and gene therapy — projected to reach 20% of the top-100 drugs by value by 2030. He also pointed to the remarkable tenfold increase in Indian healthcare and life sciences startups, from 900 in 2020 to over 10,000 in 2024.

The PRIP scheme aims to build on this momentum with support from initiatives like CSIR’s INTENT for clinical trials, ICMR’s MedTech Mitra and Patent Mitra, and funding programs like DST’s Quantum Computing Mission and MeitY’s TIDE 2.0 and SAMRIDH. Leaders from DST, MeitY, DHR, and CSIR stressed the importance of digital health, AI, data-driven technologies, and industry-academia collaboration in driving innovation and commercialisation of research.

The workshop hosted over 100 participants from top scientific institutions, including NIPERs, IITs, CSIR labs, and government bodies, with discussions on emerging pharmaceutical and MedTech trends and strategies to transform research into market-ready products. Participants were invited to submit suggestions via the Expression of Interest (EoI) form on the Department of Pharmaceuticals’ website, open until April 7, 2025.

(PIB)       

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilisers, Government of India, held a workshop on the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme on March 12, 2025. Senior officials from key government departments participated, including Shri Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); Shri S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr. N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General of CSIR; and Dr. Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, ICMR.The workshop focused on strengthening India’s innovation ecosystem in pharmaceuticals and medical technology. Shri Amit Agrawal highlighted the sector's rapid growth, noting the rising global share of advanced technologies like antibody-drug conjugates and gene therapy — projected to reach 20% of the top-100 drugs by value by 2030. He also pointed to the remarkable tenfold increase in Indian healthcare and life sciences startups, from 900 in 2020 to over 10,000 in 2024.The PRIP scheme aims to build on this momentum with support from initiatives like CSIR’s INTENT for clinical trials, ICMR’s MedTech Mitra and Patent Mitra, and funding programs like DST’s Quantum Computing Mission and MeitY’s TIDE 2.0 and SAMRIDH. Leaders from DST, MeitY, DHR, and CSIR stressed the importance of digital health, AI, data-driven technologies, and industry-academia collaboration in driving innovation and commercialisation of research.The workshop hosted over 100 participants from top scientific institutions, including NIPERs, IITs, CSIR labs, and government bodies, with discussions on emerging pharmaceutical and MedTech trends and strategies to transform research into market-ready products. Participants were invited to submit suggestions via the Expression of Interest (EoI) form on the Department of Pharmaceuticals’ website, open until April 7, 2025.(PIB)       

Related Stories

Gold Stories

Next Story
Infrastructure Energy

Asian Energy Services Q1 FY27 PAT Rises 129 Per Cent

Asian Energy Services Limited reported a 129 per cent year-on-year rise in net profit to Rs 128 million for Q1 FY27, compared with the corresponding quarter last year.Revenue increased 135 per cent year-on-year to Rs 2.71 billion, supported by continued momentum across its services business, disciplined execution and contributions from domestic and international operations. EBITDA grew 81 per cent year-on-year during the quarter.As of June 30, 2026, the company’s standalone order book stood at Rs 17.54 billion, with around 60 per cent coming from oil and gas services and 40 per cent from min..

Next Story
Infrastructure Urban

BioBTX to Build First Commercial-Scale Circular Chemicals Plant

Dutch circular chemistry technology developer BioBTX is building what it says will be the world’s first commercial-scale plant to convert mixed plastic waste into high-quality aromatic chemicals using its proprietary Integrated Catalytic Cracking Process (ICCP) technology.The facility will be built at Chemical Park Delfzijl on the northern coast of the Netherlands and is expected to create 35 jobs. Covestro, which has been a shareholder and strategic partner of BioBTX since 2024, holds a mid-single-digit million-euro investment in the company.BioBTX’s ICCP technology uses catalytic pyrolys..

Next Story
Real Estate

Awfis Q1 FY27 PAT Jumps 140% as Revenue Rises 27%

Awfis Space Solutions reported a 140 per cent year-on-year rise in consolidated profit after tax (PAT) to Rs 240 million for Q1 FY27, compared with Rs 100 million in the corresponding quarter last year.Revenue from operations increased 27 per cent to Rs 4.25 billion from Rs 3.35 billion, while EBITDA rose 28 per cent to Rs 1.62 billion. EBITDA margin improved to 38.2 per cent from 37.8 per cent. Profit before tax increased 135 per cent to Rs 240 million.The company's co-working business recorded 27 per cent year-on-year growth, supported by demand from enterprises, Global Capability Centres (G..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement